Gyre Therapeutics IncNASDAQ:GYRENASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE15.0200
- TODAY'S CHANGE (%)0.0400 (0.2670%)
- Bid / Lots14.5000/ 1
- Ask / Lots15.0700/ 8
- Open / Previous Close15.0600 / 14.9800
- Day Range
- 52 Week Range
- Volume32,303
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GYRE |
|---|---|---|
| 09:32 ET | 451 | 15.06 |
| 09:39 ET | 400 | 15.05 |
| 09:41 ET | 1912 | 15.06 |
| 09:45 ET | 250 | 14.98 |
| 09:50 ET | 1430 | 15.12 |
| 10:08 ET | 188 | 15.0001 |
| 10:21 ET | 305 | 15 |
| 10:32 ET | 100 | 14.99 |
| 10:35 ET | 100 | 14.91 |
| 11:11 ET | 1100 | 14.91 |
| 11:15 ET | 100 | 14.91 |
| 11:29 ET | 506 | 14.82 |
| 12:30 ET | 200 | 14.88 |
| 12:32 ET | 600 | 14.85 |
| 12:36 ET | 200 | 14.84 |
| 12:45 ET | 100 | 14.96 |
| 12:48 ET | 100 | 14.85 |
| 12:57 ET | 200 | 14.935 |
| 12:59 ET | 100 | 14.9 |
| 01:08 ET | 142 | 14.9 |
| 01:15 ET | 100 | 14.945 |
| 01:19 ET | 100 | 14.945 |
| 01:32 ET | 100 | 14.89 |
| 01:55 ET | 100 | 15.05 |
| 02:02 ET | 100 | 15.06 |
| 02:31 ET | 200 | 15.04 |
| 02:47 ET | 100 | 15.04 |
| 02:56 ET | 100 | 14.97 |
| 03:00 ET | 300 | 14.95 |
| 03:02 ET | 100 | 14.975 |
| 03:03 ET | 100 | 14.975 |
| 03:05 ET | 200 | 14.9301 |
| 03:07 ET | 100 | 14.88 |
| 03:09 ET | 569 | 14.9 |
| 03:23 ET | 200 | 14.935 |
| 03:57 ET | 200 | 15.04 |
| 03:59 ET | 100 | 15.02 |
Jul 2, 2024
DJ Gyre Wins China Approval for Tablet to Treat Thrombocytopenia, from 4:32PM ET on Tuesday Jul 02, 2024 by Dow Jones
4:32PM ET on Tuesday Jul 02, 2024 by Dow JonesGyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia, from 4:05PM ET on Tuesday Jul 02, 2024 by Dow Jones
4:05PM ET on Tuesday Jul 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Gyre Therapeutics Inc | 1.3B | -8.0x | --- |
Ardelyx Inc | 1.3B | -19.5x | --- |
Arcus Biosciences Inc | 1.4B | -5.1x | --- |
Prothena Corporation PLC | 1.3B | -7.5x | --- |
Nurix Therapeutics Inc | 1.4B | -7.5x | --- |
Vir Biotechnology Inc | 1.5B | -2.7x | --- |
Company Information
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.
Contact Information
- Headquarters
- 12770 High Bluff Drive, Suite 150SAN DIEGO, CA, United States 92130
- Phone
- 619-949-3681
- Fax
- 302-636-5454
Executives
- Non-Executive Chairman of the Board
- Ying Luo
- President, Director
- Songjiang Ma
- Chief Executive Officer, Director
- Han Ying
- Interim Chief Financial Officer
- Ruoyu Chen
- Chief Operating Officer
- Weiguo Ye
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
|---|---|
Revenue (TTM) | $140.6M |
Shares Outstanding | 85.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.04 |
EPS | $-1.88 |
Book Value | $0.64 |
P/E Ratio | -8.0x |
Price/Sales (TTM) | 9.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -42.20% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
